Sign in
CompletedPhase 4

Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study

Key facts

Who runs it
Fayoum University Hospital
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
180 people enrolled
Started
14 Jan 2024
Ended
1 Feb 2025
Type of study
Interventional, 3 groups
Treatments tested
  • L-Arginine
  • Tadalafil 5 mg
Record updated
27 April 2025

Who can take part

Age
45 years to 75 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • • Naive ( not previously treated) male patient with mild to moderate ED according to SHIM Questionnaire

Who cannot take part

  • ● Kidney disease or liver failure; Coronary heart disease; Peyronie's disease; Neurological disease that may related to ED

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Introduction Sexual dysfunctions are annoying health problems with the erectile problems forming the main part of them. Erectile dysfunction (ED) is defined as the persistent inability to obtain or maintain an erection that is sufficient to allow satisfactory sexual intercourse.[1] Aim of Work To evaluate the role of L-arginine monotherapy versus Tadalafil monotherapy versus their combination for the treatment of erectile dysfunction .

Read full original descriptionShow less

Patients and methods:

Inclusion criteria:

• Naive ( not previously treated) male patient with mild to moderate ED according to SHIM Questionnaire.

Exclusion criteria:

* Kidney disease or liver failure * Coronary heart disease * Peyronie's disease * Neurological disease that may related to ED

The 3 groups in the trial

  • Group ATreatment being tested

    was given daily 3 g(three divided doses) oral tablets of L-arginine for eight weeks

    Treatment: L-Arginine

  • Group BTreatment being tested

    was given daily 5 mg oral tablets of Tadalafil for eight weeks.

    Treatment: Tadalafil 5 mg

  • Group CTreatment being tested

    was given daily 3 g oral tablets of L-arginine and 5 mg oral tablets of Tadalafil for eight weeks.

    Treatment: L-Arginine and Tadalafil 5 mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 April 2025